XPH(SZ:300147)2022-12-06 08:20Group 1: Marketing and Sales Strategy - The company is transitioning its traditional Chinese medicine sales model from a distributor-based approach to a self-managed direct sales model, enhancing control over terminal sales [2][3] - The sales team is being restructured to operate OTC and prescription drugs independently, while also implementing nationwide price maintenance and abandoning low-bid regions [3] Group 2: Development Plans - The company aims to establish technical standards for approximately 400 varieties of traditional Chinese medicine granules within two years, focusing on industry policy and quality standards [3] - Production bases are being developed in Ningxia Longde and Sichuan Nanchong to support the future production of granules [3] Group 3: Clinical Projects - The company is collaborating with 458 hospitals on a specific T-cell therapy project for solid tumors, with the first phase of clinical trials completed and the second phase currently in patient selection [4] Group 4: Employee Stock Ownership Plan - The first phase of the employee stock ownership plan is currently at a loss, and the company will consider follow-up measures before the plan's expiration, subject to official announcements [4] Group 5: Future Directions - The company continues to focus on the pharmaceutical and healthcare industry, with an emphasis on traditional Chinese medicine and plans to expand into precision medicine [4] - The investment in Huacheng Life Insurance is based on future business synergies, with the company awaiting regulatory approval [5]